Prenetics Global (NASDAQ:PRE) Trading Up 1.8% – Should You Buy?

Prenetics Global Limited (NASDAQ:PRE)’s stock price was up 1.8% during trading on Tuesday . The stock traded as high as $7.95 and last traded at $7.72. Approximately 39,977 shares traded hands during mid-day trading, an increase of 5% from the average daily volume of 38,229 shares. The stock had previously closed at $7.58.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Prenetics Global to a “hold” rating in a research report on Saturday, July 5th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.00.

Prenetics Global Trading Up 1.8%

The company’s 50 day moving average is $8.03 and its 200-day moving average is $6.36. The company has a market capitalization of $100.21 million, a P/E ratio of -1.93 and a beta of 0.15.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings results on Thursday, June 12th. The company reported ($0.80) earnings per share (EPS) for the quarter. The business had revenue of $17.31 million during the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. Prenetics Global has set its FY 2025 guidance at EPS. Q2 2025 guidance at EPS. Analysts predict that Prenetics Global Limited will post -3.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Prenetics Global stock. Nomura Holdings Inc. lifted its position in Prenetics Global Limited (NASDAQ:PRE) by 3.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 333,528 shares of the company’s stock after buying an additional 10,576 shares during the period. Nomura Holdings Inc. owned about 2.73% of Prenetics Global worth $1,307,000 as of its most recent SEC filing. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.